{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:11:50Z","timestamp":1779088310906,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd013165","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000}}],"reference-count":147,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013165.pub2","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T05:31:00Z","timestamp":1593149460000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Potassium binders for chronic hyperkalaemia in people with chronic kidney disease"],"prefix":"10.1002","author":[{"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella","family":"Ruospo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria M","family":"Saglimbene","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000492622","article-title":"Patiromer to enable spironolactone use in the treatment of patients with resistant hypertension and chronic kidney disease: rationale and design of the AMBER study","volume":"48","author":"Agarwal","year":"2018","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013165.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1053\/j.ajkd.2019.04.004","article-title":"Patiromer to enable spironolactone in patients with resistant hypertension and CKD: primary results of amber [abstract]","volume":"73","author":"Agarwal","year":"2019","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0003|cit3","first-page":"14","article-title":"Patiromer vs. placebo to enable spironolactone in patients with resistant hypertension and CKD according to baseline kidney function (AMBER trial) [abstract no: TH-OR052]","volume":"30","author":"Agarwal","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10208","key":"10.1002\/14651858.CD013165.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD013165.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cardfail.2019.11.010","article-title":"Patiromer vs. placebo to enable spironolactone in patients with resistant hypertension and chronic kidney disease (AMBER): results in prespecified subgroups [abstract]","volume":"25","author":"Williams","year":"2019","journal-title":"Journal of Cardiac Failure"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.jash.2015.03.177","article-title":"Reduction of serum K+ with patiromer for 1 year in patients with diabetic CKD who developed hyperkalemia while on maximal losartan and\/or spironolactone [abstract]","volume":"9","author":"Bakris","year":"2015","journal-title":"Journal of the American Society of Hypertension"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"iii51","DOI":"10.1093\/ndt\/gfv158.03","article-title":"Patiromer lowered serum potassium for up to 1 year in hyperkalemic patients with diabetes and advanced kidney disease on RAAS inhibitors [abstract NO: SuO019]","volume":"30","author":"Bakris","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0008|cit8","first-page":"B5","article-title":"Effect of patiromer on hyperkalemia in patients with diabetic nephropathy: results of a 1-year randomized trial [abstract no: SA-PO1099]","volume":"25","author":"Bakris","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD013165.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial [Erratum appears in JAMA. 2015 Aug 18;314(7):731 Note: Dosage error in article text; PMID: 26284731]","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"iii89","DOI":"10.1093\/ndt\/gfx132.TO028","article-title":"Effect of patiromer on serum potassium in hyperkalemic patients with severe CKD on RAAS inhibitors: results from OPAL-HK and amethyst-DN [abstract no: TO028]","volume":"32","author":"Bushinsky","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0011|cit11","first-page":"996A","article-title":"High rates of hyperkalemia in patients with chronic kidney disease stage 3 or 4, diabetes, and hypertension [abstract no: PUB455]","volume":"23","author":"Cope","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ehf2.12292","article-title":"Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD013165.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.hrtlng.2015.10.013","article-title":"1-year safety and efficacy of patiromer for hyperkalemia in heart failure patients with chronic kidney disease on renin angiotensin-aldosterone system inhibitors [abstract]","volume":"44","author":"Pitt","year":"2015","journal-title":"Heart & Lung"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"A855","DOI":"10.1016\/S0735-1097(15)60855-5","article-title":"1-year safety and efficacy of patiromer for hyperkalemia in heart failure patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors [abstract]","volume":"65","author":"Pitt","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0015|cit15","first-page":"55","article-title":"Long-term effects of patiromer for hyperkalaemia treatment in patients with HFrEF and diabetic nephropathy on RAASi [abstract]","volume":"19","author":"Pitt","year":"2017","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0016|cit16","first-page":"591","article-title":"Long-term effect of patiromer for hyperkalaemia treatment in patients with HFmrEF and diabetic nephropathy on RAAS inhibitors [abstract no: P2206]","volume":"20","author":"Pitt","year":"2018","journal-title":"European Journal of Heart Failure"},{"issue":"8 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.cardfail.2015.06.314","article-title":"Patiromer reduces serum K+ in hyperkalemic patients with HF and CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN [abstract]","volume":"21","author":"Pitt","year":"2015","journal-title":"Journal of Cardiac Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0018|cit18","first-page":"318","article-title":"Patiromer reduced serum K+ in hyperkalaemic patients with HF and advanced CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN [abstract no: P1799]","volume":"36","author":"Pitt","year":"2015","journal-title":"European Heart Journal"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0019|cit19","first-page":"S503","article-title":"Insulin therapy for diabetes does not modify the effect of patiromer on serum potassium in hyperkalaemic patients with type 2 diabetes on RAAS inhibitors [abstract no: 1050]","volume":"59","author":"Rossignol","year":"2016","journal-title":"Diabetologia"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0020|cit20","first-page":"S533","article-title":"Patiromer lowers serum potassium in patients with elevated potassium and diabetes and advanced CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN [abstract no: 1110]","volume":"58","author":"Weir","year":"2015","journal-title":"Diabetologia"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0021|cit21","first-page":"501","article-title":"Patiromer controls serum potassium for up to 1 year in hyperkalemic patients with diabetes and advanced kidney disease on RAAS inhibitors regardless of age [abstract no: FR-PO255]","volume":"30","author":"Weir","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD013165.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0023|cit23","first-page":"2B","article-title":"Safety and efficacy of ZS 9, a novel selective cation trap, for treatment of hyperkalemia in CKD patients [abstract no: HI-OR05]","volume":"24","author":"Ash","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"A369","DOI":"10.1016\/S0735-1097(14)60369-7","article-title":"ZS-9, a novel selective cation trap, leads to a rapid and predictable rate of decline in serum potassium in patients with chronic kidney disease and hyperkalemia [abstract]","volume":"63","author":"Singh","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/j.jash.2014.03.155","article-title":"Change from baseline in serum K+ with ZS-9 in patients with chronic kidney disease treated for hyperkalemia [abstract]","volume":"8","author":"Singh","year":"2014","journal-title":"Journal of the American Society of Hypertension"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.jash.2014.03.028","article-title":"Effect of ZS-9, a novel selective cation trap, on urinary potassium and sodium excretion when used for the treatment of hyperkalemia in patients with chronic kidney disease [abstract]","volume":"8","author":"Singh","year":"2014","journal-title":"Journal of the American Society of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD013165.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"A103","DOI":"10.1053\/j.ajkd.2014.01.354","article-title":"ZS-9, a novel selective cation trap, does not significantly increase sodium excretion when used for the treatment of hyperkalemia in patients with CKD [abstract no: 337]","volume":"63","author":"Singh","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0028|cit28","first-page":"iii155","article-title":"Acid-base balance in a phase 2 trial of ZS-9 for hyperkalaemia in patients with chronic kidney disease [abstract no: SP251]","volume":"29","author":"Singh","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD013165.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1681\/ASN.2019050450","article-title":"A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia","volume":"30","author":"Fishbane","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0030|cit30","first-page":"95","article-title":"Sodium zirconium cyclosilicate (SZC) improves potassium balance in hyperkalemic hemodialysis patients: results from the phase 3b, randomized, placebo-controlled DIALIZE study [abstract no: SA-OR061]","volume":"30","author":"Fishbane","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD013165.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1681\/ASN.V9101924","article-title":"Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease","volume":"9","author":"Gruy-Kapral","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0735-1097(16)31346-8","article-title":"Rapid onset of potassium: Lowering with sodium zirconium cyclosilicate (ZS-9) across patients stratified by race, age, and comorbidities in the randomized, double-blind, placebo-controlled phase 3 HARMONIZE study [abstract]","volume":"67","author":"Alpert","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"iii66","DOI":"10.1093\/ndt\/gfv165.03","article-title":"Achievement and maintenance of normokalaemia in patients with non-dialysis stage 5 chronic kidney disease [abstract no: FP003]","volume":"30","author":"De Francisco","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"iii6","DOI":"10.1093\/ndt\/gfv137.02","article-title":"Normalization of serum bicarbonate with sodium zirconium cyclosilicate (ZS-9) in the phase 3 randomized, double-blind, placebo-controlled HARMONIZE study [abstract no: FO012]","volume":"30","author":"De Francisco","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"A842","DOI":"10.1016\/S0735-1097(15)60842-7","article-title":"Treatment of hyperkalemia with ZS-9, a selective nonabsorbed cation exchange resin, does not lead to hypomagnesemia: results from two multicenter, randomized, double blind, placebo-controlled phase 3 trials [abstract]","volume":"65","author":"El-Shahawy","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"iii66","DOI":"10.1093\/ndt\/gfv165.01","article-title":"Effect of sodium zirconium cyclosilicate (ZS-9) on urinary potassium and sodium: an analysis of the phase 3 randomized, double-blind, placebo-controlled HARMONIZE study [abstract no: FP001]","volume":"30","author":"Jadoul","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"21","key":"10.1002\/14651858.CD013165.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.[Erratum in: JAMA. 2015 Feb 3;313(5):526. Dosage error in text]","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"A54","DOI":"10.1053\/j.ajkd.2015.02.159","article-title":"Sodium zirconium cyclosilicate (ZS-9) for hyperkalemia in stage 4\/5 CKD subgroup of the phase 3 HARMONIZE study [abstract no: 157]","volume":"65","author":"Lerma","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.annemergmed.2015.07.291","article-title":"Sodium zirconium cyclosilicate for patients with severe hyperkalemia: Subgroup analysis of the phase 3, international, multicenter, randomized, double-blind, placebo-controlled HARMONIZE trial [abstract no: 257]","volume":"66","author":"Levy","year":"2015","journal-title":"Annals of Emergency Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"iii68","DOI":"10.1093\/ndt\/gfv165.07","article-title":"Efficiency of sodium zirconium cyclosilicate (ZS-9) increases with severity of hyperkalaemia: subgroup analysis of patients stratified by baseline potassium in the phase 3 HARMONIZE study [abstract no: FP007]","volume":"30","author":"Mann","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"iii69","DOI":"10.1093\/ndt\/gfv165.10","article-title":"Maintenance of normal serum potassium with sodium zirconium cyclosilicate (ZS-9) in subgroup of patients with history of chronic kidney disease and on RAAS inhibitors from the phase 3 randomized, double-blind, placebo-controlled harmonize study [abstract no: FP010]","volume":"30","author":"Packham","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0042|cit42","first-page":"S69","article-title":"Sodium zirconium cyclosilicate (ZS-9) for severe hyperkalemia: a post-HOC analysis of the phase 3 HARMONIZE trial [abstract no: 143]","volume":"22","author":"Peacock","year":"2015","journal-title":"Academic Emergency Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"A69","DOI":"10.1053\/j.ajkd.2015.02.222","article-title":"Safety of sodium zirconium cyclosilicate (ZS-9) in hyperkalemia: analysis of GI effects in the phase 3 HARMONIZE study [abstract no: 220]","volume":"65","author":"Qunibi","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"A70","DOI":"10.1053\/j.ajkd.2015.02.223","article-title":"Sodium zirconium cyclosilicate (ZS-9) in hyperkalemic patients with CKD on RAAS inhibitors: subgroup analysis of phase 3 HARMONIZE study [abstract no: 221]","volume":"65","author":"Qunibi","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"iii68","DOI":"10.1093\/ndt\/gfv165.08","article-title":"Achievement of normal serum potassium with sodium zirconium cyclosilicate (ZS-9) in a subgroup of patients with stage 4\/5 chronic kidney disease and baseline potassium >=5.5 mmol\/L from the phase 3 randomized, double-blind, placebo-controlled HARMONIZE study [abstract no: FP008]","volume":"30","author":"Roger","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0046|cit46","first-page":"e56","article-title":"The effectiveness of ZS-9 in achieving normokalemia during the open-label phase of the HARMONIZE trial [abstract]","volume":"9","author":"Spinowitz","year":"2015","journal-title":"Journal of the American Society of Hypertension"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0047|cit47","first-page":"e56","article-title":"ZS-9 for treatment of hyperkalemia in black patients: subgroup analysis from the phase 3 HARMONIZE study [abstract]","volume":"9","author":"Spinowitz","year":"2015","journal-title":"Journal of the American Society of Hypertension"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0048|cit48","first-page":"B7","article-title":"Sodium zirconium cyclosilicate for hyperkalemia: results of the randomized, placebo-controlled, multi-dose HARMONIZE-GLOBAL study [abstract no: TH-PO1158]","volume":"29","author":"Zannad","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1097\/01.hjh.0000468799.18826.ad","article-title":"Sodium zirconium cyclosilicate for treatment of hyperkalaemia: analysis of patients on renin-angiotensin-aldosterone inhibitors (RAASi) from the phase 3 HARMONIZE study [abstract no: PP.35.03]","volume":"33","author":"Zannad","year":"2015","journal-title":"Journal of Hypertension"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0050|cit50","first-page":"342","article-title":"Effect of sodium zirconium cyclosilicate (ZS-9) on aldosterone from the phase 3 randomized, double-blind, placebo-controlled HARMONIZE study [abstract no: P1592]","volume":"17","author":"Zannad","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0051|cit51","first-page":"B7","article-title":"Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a dose-finding study [abstract no: TH-PO1157]","volume":"29","author":"Kashihara","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0052|cit52","first-page":"846a","article-title":"Sodium polystyrene sulfonate for the treatment of mild hyperkalemia in chronic kidney disease: a randomized clinical trial [abstract no: SA-PO926]","volume":"26","author":"Desforges","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD013165.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD013165.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10157-017-1412-y","article-title":"Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia","volume":"22","author":"Nakayama","year":"2018","journal-title":"Clinical & Experimental Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0055|cit55","first-page":"455","article-title":"Treatment of hyperkalemia in patients with chronic kidney disease: a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate","volume":"26","author":"Nasir","year":"2014","journal-title":"Journal of Ayub Medical College, Abbottabad: JAMC"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"iii89","DOI":"10.1093\/ndt\/gfx132.TO028","article-title":"Effect of patiromer on serum potassium in hyperkalemic patients with severe CKD on RAAS inhibitors: Results from OPAL-HK and amethyst-DN [abstract no: TO028]","volume":"32","author":"Bushinsky","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD013165.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"8 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.cardfail.2015.06.314","article-title":"Patiromer reduces serum K+ in hyperkalemic patients with HF and CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN [abstract]","volume":"21","author":"Pitt","year":"2015","journal-title":"Journal of Cardiac Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0059|cit59","first-page":"318","article-title":"Patiromer reduced serum K+ in hyperkalaemic patients with HF and advanced CKD on RAAS inhibitors: results from OPAL-HK and AMETHYST-DN [abstract no: P1799]","volume":"36","author":"Pitt","year":"2015","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD013165.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.hrtlng.2015.10.014","article-title":"Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: results from OPAL-HK [abstract no: 9]","volume":"44","author":"Pitt","year":"2015","journal-title":"Heart & Lung"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0061|cit61","first-page":"90","article-title":"Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: results from OPAL-HK [abstract no: P397]","volume":"17","author":"Pitt","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0062|cit62","first-page":"S503","article-title":"Insulin therapy for diabetes does not modify the effect of patiromer on serum potassium in hyperkalaemic patients with type 2 diabetes on RAAS inhibitors [abstract no: 1050]","volume":"59","author":"Rossignol","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/j.jval.2018.09.2690","article-title":"A cost-effectiveness analysis of RAASI - enabling patiromer for the treatment of hyperkalemia in Austria [abstract no: PSY115]","volume":"21","author":"Walter","year":"2018","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0064|cit64","article-title":"Patiromer decreased aldosterone, urine albumin\/creatinine ratio, and blood pressure in patients with chronic kidney disease and hyperkalemia on RAAS inhibitors: results from OPAL-HK [abstract no: P602]","volume":"66","author":"Weir","year":"2015","journal-title":"Hypertension"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.jash.2015.03.133","article-title":"Patiromer increased time to RAAS inhibitor discontinuation compared with placebo in advanced CKD patients with hyperkalemia [abstract]","volume":"9","author":"Weir","year":"2015","journal-title":"Journal of the American Society of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"A90","DOI":"10.1053\/j.ajkd.2015.02.303","article-title":"Patiromer reduced recurrent hyperkalemia in advanced CKD patients on RAASI [abstract no: 301]","volume":"65","author":"Weir","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0067|cit67","first-page":"550A","article-title":"Patiromer lowers serum K+ and prevents recurrent hyperkalemia in patients with diabetes and CKD on RAAS inhibitors:subgroup results of a phase 3 trial [abstract no: FR-PO792]","volume":"25","author":"Weir","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0069|cit69","first-page":"555A","article-title":"Patiromer reduced RAASi dose discontinuations in CKD patients with moderate-to-severe hyperkalemia [abstract no: FR-PO810]","volume":"25","author":"Weir","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.kint.2016.04.019","article-title":"Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors","volume":"90","author":"Weir","year":"2016","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0071|cit71","first-page":"4B","article-title":"A two-part trial of patiromer for the treatment of hyperkalemia in chronic kidney disease subjects on renin angiotensin aldosterone system inhibition [abstract no: SA-PO1085]","volume":"24","author":"Weir","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013165.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.amjmed.2017.11.011","article-title":"Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors","volume":"131","author":"Weir","year":"2018","journal-title":"American Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0073|cit73","first-page":"10A","article-title":"Patiromer lowers serum K+ and prevents recurrent hyperkalemia in CKD patients >65 years of age on RAAS inhibitors.[abstract no: TH-OR035]","volume":"26","author":"Weir","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/HJH.0000000000001278","article-title":"Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics","volume":"35","author":"Weir","year":"2017","journal-title":"Journal of Hypertension"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"A878","DOI":"10.1016\/S0735-1097(15)60878-6","article-title":"Acute-phase efficacy of ZS-9 in patients with baseline serum potassium levels above 5.5 MEQ\/l: analysis from a phase 3, multicenter, randomized, double blind, placebo-controlled trial [abstract]","volume":"65","author":"El-Shahawy","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"iii178","DOI":"10.1093\/ndt\/gfu150","article-title":"Acute-phase efficacy in a phase 3 multicenter, randomised, double-blind, placebo-controlled trial of ZS-9 for hyperkalaemia [abstract no: SP320]","volume":"29","author":"El-Shahawy","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0077|cit77","first-page":"669A","article-title":"Once daily ZS-9 for treatment of hyperkalemia: achievement and maintenance of normokalemia in black patients in a phase 3, multicenter, randomized, double-blind, placebo-controlled trial [abstract no: SA-PO152]","volume":"25","author":"El-Shahawy","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0078|cit78","first-page":"722","article-title":"Maintenance of normal serum K+ with ZS-9 once daily in patients with CHF: subgroup analysis of a phase 3 multicenter, randomised, double-blind placebo-controlled trial of patients with hyperkalaemia [abstract no: 4140]","volume":"35","author":"El-Shahawy","year":"2014","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0079|cit79","article-title":"Maintenance of normokalemia with ZS-9 once daily in CHF patients on RAAS inhibitors: subgroup analysis of a phase 3 multicenter, randomized, double-blind, placebo-controlled trial of patients with hyperkalemia [abstract no: 503]","volume":"64","author":"El-Shahawy","year":"2014","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0081|cit81","first-page":"iii184","article-title":"Safety and tolerability of ZS-9 in a multicenter, randomised, double-blind, placebo-controlled trial in patients with hyperkalaemia [abstract no: SP337]","volume":"29","author":"Packham","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0082|cit82","first-page":"B5","article-title":"ZS-9 effectively reduces potassium levels in hyperkalemic diabetic patients who have both renal impairment and a history of heart failure [abstract no: SA-PO1100]","volume":"25","author":"Packham","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"A792","DOI":"10.1016\/S0735-1097(15)60792-6","article-title":"ZS-9 maintains normokalemia in hyperkalemic patients despite continuing RAAS inhibitors: a subgroup analysis from a phase 3 multicenter, randomized, double blind, placebo-controlled trial [abstract]","volume":"65","author":"Qunibi","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0084|cit84","first-page":"A142","article-title":"Once-daily ZS-9, a novel selective potassium trap, maintained normokalemia in patients with diabetes after acute therapy for hyperkalemia [abstract no: 553-P]","volume":"63","author":"Rasmussen","year":"2014","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0085|cit85","first-page":"A296","article-title":"ZS-9, a novel selective potassium trap, rapidly reduced serum potassium in patients with diabetes treated for hyperkalemia [abstract no: 1139-P]","volume":"63","author":"Rasmussen","year":"2014","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0086|cit86","first-page":"iii180","article-title":"Efficacy of ZS-9 in patients receiving RAAS therapy: a subgroup analysis of a phase 3 multicenter, randomised, double-blind, placebo-controlled trial [abstract no: SP324]","volume":"29","author":"Roger","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0087|cit87","first-page":"iii182","article-title":"Extended efficacy of ZS-9 once-daily in a phase 3 multicenter, randomised, double-blind, placebo-controlled trial of patients with hyperkalaemia [abstract no: SP331]","volume":"29","author":"Roger","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0088|cit88","first-page":"667A","article-title":"Effect of ZS-9 on serum bicarbonate and BUN in a phase 3 randomized, double-blind, placebo-controlled trial [abstract no: SA-PO147]","volume":"25","author":"Roger","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0089|cit89","article-title":"Achievement of normokalemia with ZS-9 across subgroups in a phase 3 multicenter, randomized, double-blind, placebo-controlled trial of patients with hyperkalemia [abstract no: 635]","volume":"64","author":"Singh","year":"2014","journal-title":"Hypertension"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0090|cit90","first-page":"576A","article-title":"Phase 3, multicenter, randomised, double-blind, placebo-controlled trial of once-daily ZS-9 for treatment of hyperkalemia: achievement and maintenance of k+ in subgroup analysis of patients with significant renal impairment [abstract no: FR-PO896]","volume":"25","author":"Singh","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013165.pub2-BIB0091|cit91","first-page":"A17489","article-title":"Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of once-daily ZS-9 for treatment of hyperkalemia: achievement and maintenance of K+ in subgroup analysis of patients with heart failure not on RAAS inhibitors [abstract no: A14686]","volume":"130","author":"Singh","year":"2014","journal-title":"Circulation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0092|cit92","first-page":"75A","article-title":"Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of once-daily ZS-9 for treatment of hyperkalemia: achievement and maintenance of K+ in subgroup analysis of patients with significant renal impairment and diabetes [abstract no: FR-OR123]","volume":"25","author":"Singh","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013165.pub2-BIB0093|cit93","first-page":"iii178","article-title":"Phase 3, multicenter, randomised, double-blind, placebo-controlled trial of ZS-9: subgroup analysis stratified by baseline serum potassium levels [abstract no: SP321]","volume":"29","author":"Singh","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0094|cit94","article-title":"Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of once-daily ZS-9 for treatment of hyperkalemia: maintenance of serum K+ in subgroup analysis of patients on RAAS therapy [abstract no: 508]","volume":"64","author":"Singh","year":"2014","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jash.2014.07.014","article-title":"ZS-9 once-daily maintained serum K+ in hyperkalemic subjects on RAAS therapy: Subgroup analysis from a phase 3, multicenter, randomized, double-blind, placebo-controlled trial [abstract]","volume":"8","author":"Singh","year":"2014","journal-title":"Journal of the American Society of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"A91","DOI":"10.1053\/j.ajkd.2015.02.309","article-title":"Placebo effect in clinical studies in hyperkalemia: a double-blind, randomized, placebo-controlled phase 3 study of sodium zirconium cyclosilicate (ZS-9) [abstract no: 307]","volume":"65","author":"Yang","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0097|cit97","first-page":"483A","article-title":"RLY5016: A novel, effective, non-absorbed, oral polymer for the control of serum potassium in heart failure and chronic kidney disease [abstract no: F-PO1617]","volume":"21","author":"Bushinsky","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD013165.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"European Heart Journal"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0099|cit99","first-page":"163","article-title":"Effects of patiromer on markers of mineral metabolism in patients with hyperkalemia and hyperphosphatemia [abstract no: TH-PO199]","volume":"29","author":"Bushinsky","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013165.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2215\/CJN.04500418","article-title":"Effects of the potassium-binding polymer patiromer on markers of mineral metabolism","volume":"14","author":"Bushinsky","year":"2019","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD013165.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/1074248418788334","article-title":"Effect of patiromer in hyperkalemic patients taking and not taking RAAS inhibitors","volume":"23","author":"Kloner","year":"2018","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0102|cit102","article-title":"Effect of patiromer in hyperkalemic patients with or without RAASi [abstract no: 14680]","volume":"136","author":"Kloner","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000481270","article-title":"Patiromer lowers serum potassium when taken without food: comparison to dosing with food from an open-label, randomized, parallel group hyperkalemia study","volume":"46","author":"Pergola","year":"2017","journal-title":"American Journal of Nephrology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013165.pub2-BIB0104|cit104","first-page":"S559","article-title":"Serum potassium control and patiromer taken without or with food in hyperkalaemic patients with diabetes [abstract no: 1214]","volume":"60","author":"Rossignol","year":"2017","journal-title":"Diabetologia"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1016\/j.ekir.2019.05.793","article-title":"Efficacy and safety of once-daily patiromer by baseline serum potassium level: post-hoc results from the TOURMALINE trial [abstract no: SUN-288]","volume":"4","author":"Weir","year":"2019","journal-title":"Kidney International Reports"},{"issue":"6","key":"10.1002\/14651858.CD013165.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/1744-9987.12723","article-title":"Calcium-polystyrene sulfonate decreases inter-dialytic hyperkalemia in patients undergoing maintenance hemodialysis: a prospective, randomized, crossover study","volume":"22","author":"Wang","year":"2018","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0107|cit107","unstructured":"Ni Z Reduce incidence of pre-dialysis hyperkalaemia with sodium zirconium cyclosilicate in Chinese subjects (DIALIZE China) www.clinicaltrials.gov\/ct2\/show\/NCT04217590"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0108|cit108","unstructured":"Goehring UM Patiromer for the management of hyperkalemia in subjects receiving RAASi medications for the treatment of heart failure (DIAMOND) www.clinicaltrials.gov\/ct2\/show\/NCT03888066"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0109|cit109","unstructured":"Middleton JP Patiromer efficacy to reduce episodic hyperkalemia in end stage renal disease patients www.clinicaltrials.gov\/ct2\/show\/NCT03781089"},{"issue":"4-a Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.18553\/jmcp.2017.23.4-a.s2","article-title":"Focus on hyperkalemia management: expert consensus and economic impacts","volume":"23","author":"Alvarez","year":"2017","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"10","key":"10.1002\/14651858.CD013165.pub2-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010344.pub2","article-title":"Pharmacological interventions for the acute management of hyperkalaemia in adults","author":"Batterink","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD013165.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/03007995.2018.1433141","article-title":"The prevalence of hyperkalemia in the United States","volume":"34","author":"Betts","year":"2018","journal-title":"Current Medical Research & Opinion"},{"issue":"2","key":"10.1002\/14651858.CD013165.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines","volume":"41","author":"Bozkurt","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"2333794X1775400","DOI":"10.1177\/2333794X17754005","article-title":"Hyperkalemia was an independent risk factor for death while under mechanical ventilation among children hospitalized with diarrhea in Bangladesh","volume":"5","author":"Chowdhury","year":"2018","journal-title":"Global Pediatric Health"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MNH.0000000000000320","article-title":"Advances in the management of hyperkalemia in chronic kidney disease","volume":"26","author":"Cowan","year":"2017","journal-title":"Current Opinion in Nephrology & Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD013165.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0897190017692921","article-title":"Efficacy and safety of patiromer in hyperkalemia: a systematic review and meta-analysis","volume":"31","author":"Das","year":"2018","journal-title":"Journal of Pharmacy Practice"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1074248417741685","article-title":"Evaluation of the pharmacodynamic effects of the potassium binder RDX7675 in mice","volume":"23","author":"Davidson","year":"2017","journal-title":"Journal of Cardiovascular Pharmacology & Therapeutics"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0119|cit119","first-page":"S307","article-title":"The burden of hyperkalemia in patients with cardiovascular and renal disease","volume":"21","author":"Dunn","year":"2015","journal-title":"American Journal of Managed Care"},{"issue":"12","key":"10.1002\/14651858.CD013165.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0121|cit121","unstructured":"Drug approval. Veltassa (Patiromer) powder for oral suspension. Application No: 205739. Approved October 21, 2015 www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/205739Orig1s000Approv.pdf"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0122|cit122","unstructured":"Drug approval. Lokelma (sodium zirconium cyclosilicate) for oral suspension. Application No: 207078. Approved May 18, 2018 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207078s000lbl.pdf"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.kisu.2017.09.001","article-title":"New options for the management of chronic hyperkalemia","volume":"7","author":"Fried","year":"2017","journal-title":"Kidney International Supplements"},{"issue":"7650","key":"10.1002\/14651858.CD013165.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013165.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD013165.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0127|cit127","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD013165.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).[Erratum in JAMA. 2014 May 7;311(17):1809]","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD013165.pub2-BIB0129|cit129","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney International Supplements"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0130|cit130","first-page":"S27","article-title":"Managing hyperkalemia in high-risk patients in long-term care","volume":"23","author":"Kumar","year":"2017","journal-title":"American Journal of Managed Care"},{"issue":"2","key":"10.1002\/14651858.CD013165.pub2-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003235.pub2","article-title":"Emergency interventions for hyperkalaemia","author":"Mahoney","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013165.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013165.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD013165.pub2-BIB0134|cit134","first-page":"HS15","article-title":"Updated treatment options in the management of hyperkalemia","volume":"42","author":"Ng","year":"2017","journal-title":"U.S. Pharmacist"},{"issue":"2","key":"10.1002\/14651858.CD013165.pub2-BIB0135|cit135","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13052","article-title":"Evidence in support of hyperkalaemia management strategies: A systematic literature review","volume":"72","author":"Palaka","year":"2018","journal-title":"International Journal of Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD013165.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"4-a Suppl","key":"10.1002\/14651858.CD013165.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.18553\/jmcp.2017.23.4-a.s10","article-title":"Expert panel recommendations for the identification and management of hyperkalemia and role of patiromer in patients with chronic kidney disease and heart failure","volume":"23","author":"Rafique","year":"2017","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"8","key":"10.1002\/14651858.CD013165.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized ALdactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0139|cit139","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0140|cit140","unstructured":"Schunemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD013165.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","article-title":"The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure","volume":"46","author":"Shah","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0142|cit142","unstructured":"The SONG Handbook Version 1.0 www.songinitiative.org\/reports-and-publications\/"},{"issue":"1","key":"10.1002\/14651858.CD013165.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","article-title":"New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors","volume":"32","author":"Tamargo","year":"2018","journal-title":"Cardiovascular Drugs & Therapy"},{"key":"10.1002\/14651858.CD013165.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/B978-0-323-05876-6.00009-5","volume-title":"Comprehensive Clinical Nephrology","author":"Weiner","year":"2010"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013165.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"e0173542","DOI":"10.1371\/journal.pone.0173542","article-title":"Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients","volume":"12","author":"Yu","year":"2017","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"11","key":"10.1002\/14651858.CD013165.pub2-BIB0147|cit147","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013165","article-title":"Potassium binders for chronic hyperkalaemia in people with chronic kidney disease","author":"Natale","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:15:30Z","timestamp":1628550930000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD013165.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":147,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013165.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}